{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:08:34Z","timestamp":1790204914304,"version":"4.1.0"},"reference-count":150,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Ovarian clear cell carcinoma (OCCC) is a rare, aggressive epithelial ovarian cancer subtype, accounting for approximately 10% of cases and associated with a poor prognosis due to chemoresistance and unique tumor biology. OCCC is frequently linked to endometriosis and characterized by mutations in\n                    <jats:italic>ARID1A<\/jats:italic>\n                    and\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    , hyperactivation of the PI3K\/Akt\/mTOR pathway, and overexpression of VEGF, HIF-1\u03b1, and IL-6. These features drive tumor proliferation, angiogenesis, immune evasion, and resistance to platinum-based chemotherapy. The tumor microenvironment of OCCC is highly immunosuppressive, with infiltration of regulatory T cells, tumor-associated macrophages, and upregulation of immune checkpoint molecules, such as PD-1, PD-L1, and LAG-3. These characteristics suggest that the PD-1\/PD-L1 pathway plays a critical role in tumor immune evasion and could be an attractive target for therapeutic intervention. Despite the typical composition of the immunosuppressive tumor microenvironment in ovarian cancer, until now overall the results of trials testing immune checkpoint inhibitors so far have been disappointing. It is interesting to note instead that several subgroup analyses reported exceptional OCCC sensitivity to ICIs. Indeed, current and preliminary trials exploring ICIs, anti-angiogenic agents, and combinatorial therapies in OCCC show promising outcomes. Strategies targeting multiple pathways, including VEGF, IL-6, HIF-1\u03b1, and HDAC6, alongside ICIs, are under investigation to overcome resistance mechanisms. Additionally, IL-10 inhibition or ferroptosis pathway activation offers novel therapeutic potential. Personalized, biomarker-driven approaches, targeting\n                    <jats:italic>ARID1A<\/jats:italic>\n                    and\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    mutations or combining immune and anti-angiogenic agents, are gaining traction in OCCC management. This review highlights OCCC molecular underpinnings and therapeutic challenges, emphasizing the need for innovative, multi-targeted strategies. Advances in understanding genetic-immunological interplay in OCCC may enable more effective and durable treatments and improved patient outcomes.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1661048","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:35:28Z","timestamp":1764138928000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective"],"prefix":"10.3389","volume":"16","author":[{"given":"Anna","family":"Passarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Chiara","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jole","family":"Ventriglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"De Cecio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Lobianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Calvanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Lamia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sara","family":"Peluso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Stilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Venanzio","family":"Setola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","article-title":"Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics","volume":"80","author":"Prat","year":"2018","journal-title":"Hum Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1067\/j.cpradiol.2023.10.003","article-title":"Clear cell carcinoma of the ovary: Clues for radiologists to perform a correct diagnosis","volume":"53","author":"Rodrigues","year":"2024","journal-title":"Curr Probl Diagn Radiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14507","article-title":"Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis","volume":"111","author":"Suda","year":"2020","journal-title":"Cancer Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002624","article-title":"Risk of gynecologic cancer according to the type of endometriosis","volume":"131","author":"Saavalainen","year":"2018","journal-title":"Obstet Gynecol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70404-1","article-title":"Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies","volume":"13","author":"Pearce","year":"2012","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14035367","article-title":"Endometriosis-associated ovarian cancer: a review of pathogenesis","volume":"14","author":"Worley","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B8","first-page":"113","article-title":"Tumours of the ovary and peritoneum","volume-title":"Pathology and genetics: Tumours of the breast and female genital organs","author":"Tavassoli","year":"2003"},{"key":"B9","first-page":"11","article-title":"Tumours of the ovary","volume-title":"WHO classification of tumours of female reproductive organs","author":"Longacre","year":"2014"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13048-024-01359-7","article-title":"From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer","volume":"17","author":"Liu","year":"2024","journal-title":"J Ovarian Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.01.005","article-title":"Vancouver Ovarian Clear Cell Symposium Speakers. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010","volume":"121","author":"Anglesio","year":"2011","journal-title":"Gynecol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S49993","article-title":"The target therapy of ovarian clear cell carcinoma","volume":"7","author":"Jin","year":"2014","journal-title":"Onco Targets Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.10.069","article-title":"When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes","volume":"116","author":"Duska","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.012","article-title":"Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma","volume":"51","author":"Matsuo","year":"2015","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.09.005","article-title":"Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival","volume":"131","author":"Diaz","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.08.026","article-title":"Thromboembolic complications in patients with clear cell carcinoma of the ovary","volume":"104","author":"Matsuura","year":"2007","journal-title":"Gynecol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.02.006","article-title":"Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers","volume":"109","author":"Chan","year":"2008","journal-title":"Gynecol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00747.x","article-title":"Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma","volume":"99","author":"Itamochi","year":"2008","journal-title":"Cancer Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000641","article-title":"Genomic and molecular abnormalities in gynecologic clear cell carcinoma","volume":"43","author":"Marks","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e10881","DOI":"10.1097\/MD.0000000000010881","article-title":"Clear cell carcinoma of the ovary: Clinicopathologic features and outcomes in a Chinese cohort","volume":"97","author":"Tang","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2019.292","article-title":"Clinical characteristics of clear cell ovarian cancer: a retrospective multicenter experience of 308 patients in South Korea","volume":"52","author":"Lee","year":"2020","journal-title":"Cancer Res Treat"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2006.040030","article-title":"Ovarian clear cell adenocarcinoma: a continuing enigma","volume":"60","author":"Tan","year":"2007","journal-title":"J Clin Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001656","article-title":"Clear cell carcinoma of the ovary: a clinical and molecular perspective","volume":"31","author":"Iida","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.neo.2020.06.002","article-title":"Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing","volume":"22","author":"Yang","year":"2020","journal-title":"Neoplasia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000384","article-title":"The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE)","volume":"29","author":"Enomoto","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.23129","article-title":"Suppressor-type TERT mutations associated with recurrence in ovarian clear cell carcinoma","volume":"62","author":"Kobayashi","year":"2023","journal-title":"Genes Chromosomes Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.03.041","article-title":"Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma","volume":"106","author":"Lee","year":"2007","journal-title":"Gynecol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/pgp.0b013e31802d692c","article-title":"Glypican-3 expression in primary and recurrent ovarian carcinomas","volume":"26","author":"Stadlmann","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800492","article-title":"Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary","volume":"19","author":"Kato","year":"2006","journal-title":"Mod Pathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"7689","DOI":"10.1038\/s41598-021-86913-9","article-title":"Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma","volume":"11","author":"Seki","year":"2021","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e57724","DOI":"10.1371\/journal.pone.0057724","article-title":"Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis","volume":"8","author":"Yamashita","year":"2013","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2016.27.e31","article-title":"Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives","volume":"27","author":"Mabuchi","year":"2016","journal-title":"J Gynecol Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.53","article-title":"Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma","volume":"2","author":"K\u00f6bel","year":"2016","journal-title":"J Pathol Clin Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e85","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma","volume":"30","author":"Yoshida","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1038\/ncomms7118","article-title":"Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling","volume":"6","author":"Chandler","year":"2015","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134402","article-title":"Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy","volume":"130","author":"Li","year":"2020","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1038\/s41598-019-38653-0","article-title":"Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma","volume":"9","author":"Yano","year":"2019","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01550-2","article-title":"HDAC6 promotes growth, migration\/invasion, and self-renewal of rhabdomyosarcoma","volume":"40","author":"Pham","year":"2021","journal-title":"Oncogene"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114500","article-title":"Vorinostat decrease M2 macrophage polarization through ARID1A6488delG\/HDAC6\/IL-10 signaling pathway in endometriosis-associated ovarian carcinoma","volume":"161","author":"Hsieh","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.189","article-title":"Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations","volume":"25","author":"Yamamoto","year":"2012","journal-title":"Mod Pathol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2018.08.003","article-title":"Cancer-associated PIK3CA mutations in overgrowth disorders","volume":"24","author":"Madsen","year":"2018","journal-title":"Trends Mol Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00625.x","article-title":"Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis","volume":"16","author":"Yagyu","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.081000","article-title":"Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma","volume":"174","author":"Kuo","year":"2009","journal-title":"Am J Pathol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12032-019-1326-5","article-title":"Inhibition of PI3K\/AKT\/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors","volume":"37","author":"Perez-Juarez","year":"2019","journal-title":"Med Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2012.1406","article-title":"Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma","volume":"40","author":"Iida","year":"2012","journal-title":"Int J Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10756","article-title":"The mTOR\/AP-1\/VEGF signaling pathway regulates vascular endothelial cell growth","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1372330","article-title":"Regulation of ferroptosis by PI3K\/Akt signaling pathway: a promising therapeutic axis in cancer","volume":"12","author":"Su","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-24-0145","article-title":"YAP1 suppression by ZDHHC7 is associated with ferroptosis resistance and poor prognosis in ovarian clear cell carcinoma","volume":"23","author":"Furutake","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B50","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13046-018-0795-2","article-title":"PTEN lipid phosphatase inactivation links the Hippo and PI3K\/Akt pathways to induce gastric tumorigenesis","volume":"37","author":"Xu","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv615","article-title":"Regulation of PD-L1: a novel role of pro-survival signalling in cancer","volume":"27","author":"Chen","year":"2016","journal-title":"Ann Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.smim.2014.01.007","article-title":"The IL-6 feed-forward loop: a driver of tumorigenesis","volume":"26","author":"Chang","year":"2014","journal-title":"Semin Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22325","article-title":"Antitumor effects of interleukin-6 (IL-6)\/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary","volume":"55","author":"Yanaihara","year":"2016","journal-title":"Mol Carcinog"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.06.027","article-title":"Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma","volume":"146","author":"Kawabata","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01451-4","article-title":"Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma","volume":"39","author":"Mehner","year":"2020","journal-title":"Oncogene"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173817","article-title":"IL-6 promotes nuclear translocation of HIF-1\u03b1 to aggravate chemoresistance of ovarian cancer cells","volume":"894","author":"Xu","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2012.1533","article-title":"Cytokine gene expression signature in ovarian clear cell carcinoma","volume":"41","author":"Yanaihara","year":"2012","journal-title":"Int J Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0169","article-title":"Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary","volume":"9","author":"Mabuchi","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.616837","article-title":"Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment","volume":"12","author":"Bourhis","year":"2021","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4692","article-title":"Metabolic alterations caused by HNF1\u03b2 expression in ovarian clear cell carcinoma contribute to cell survival","volume":"6","author":"Amano","year":"2015","journal-title":"Oncotarget"},{"key":"B62","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12935-015-0267-0","article-title":"Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives","volume":"15","author":"Matsuzaki","year":"2015","journal-title":"Cancer Cell Int"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2018.00086","article-title":"The role of PI3K in Met driven cancer: a recap","volume":"5","author":"Hervieu","year":"2018","journal-title":"Front Mol Biosci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191067898","article-title":"Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase","volume":"98","author":"Furge","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S44941","article-title":"Emerging molecular targets in oncology: clinical potential of MET\/hepatocyte growth-factor inhibitors","volume":"7","author":"Smyth","year":"2014","journal-title":"Onco Targets Ther"},{"key":"B66","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.17179\/excli2017-948","article-title":"Microsatellite instability in colorectal cancer","volume":"17","author":"Nojadeh","year":"2018","journal-title":"EXCLI J"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.452","article-title":"Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer","volume":"107","author":"Pal","year":"2012","journal-title":"Br J Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-020-02589-1","article-title":"ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report","volume":"15","author":"Dur\u00e1n","year":"2021","journal-title":"J Med Case Rep"},{"key":"B70","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13000-021-01071-w","article-title":"Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma","volume":"16","author":"Ge","year":"2021","journal-title":"Diagn Pathol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e1277308","DOI":"10.1080\/2162402X.2016.1277308","article-title":"Clear cell ovarian cancers with microsatellite instability: a unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1\/PD-L1 expression","volume":"6","author":"Howitt","year":"2017","journal-title":"Oncoimmunology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000602","article-title":"Mismatch repair protein expression in clear cell carcinoma of the ovary: incidence and morphologic associations in 109 cases","volume":"40","author":"Bennett","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000000682","article-title":"Diffuse intratumoral stromal inflammation in ovarian clear cell carcinoma is associated with loss of mismatch repair protein and high PD-L1 expression","volume":"40","author":"Lin","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658753","article-title":"Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons","volume":"30","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00263","article-title":"Identification of genetic mutations in cancer: challenge and opportunity in the new era of targeted therapy","volume":"9","author":"Jin","year":"2019","journal-title":"Front Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653836","article-title":"e identification of prognostic genes in the tumor microenvironment of hepatocellular carcinoma","volume":"12","author":"Xiang","year":"2021","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1042\/BST20160387","article-title":"Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis","volume":"45","author":"Erdogan","year":"2017","journal-title":"Biochem Soc Trans"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1038\/oncsis.2017.54","article-title":"Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells","volume":"6","author":"Rice","year":"2017","journal-title":"Oncogenesis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071681","article-title":"Dual effect of immune cells within tumour microenvironment: pro- and anti-tumour effects and their triggers","volume":"14","author":"Pe\u00f1a-Romero","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02105","article-title":"Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma","volume":"11","author":"Maibach","year":"2020","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2019.03.001","article-title":"Translation of cancer immunotherapy from the bench to the bedside","volume":"143","author":"Guo","year":"2019","journal-title":"Adv Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0404","article-title":"Harnessing natural killer cell antitumor immunity: from the bench to bedside","volume":"7","author":"Woan","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-2990","article-title":"Macrophage-based approaches for cancer immunotherapy","volume":"81","author":"Anderson","year":"2021","journal-title":"Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2012.614","article-title":"Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-\u03b2 in acute myeloid leukemia","volume":"3","author":"Wu","year":"2012","journal-title":"Oncol Lett"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun Signal"},{"key":"B90","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia\u2013a key regulatory factor in tumour growth","volume":"2","author":"Harris","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1406655111","article-title":"Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment","volume":"111","author":"Chaturvedi","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgs123","article-title":"Tumor-associated neutrophils: friend or foe","volume":"33","author":"Fridlender","year":"2012","journal-title":"Carcinogenesis"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2008.10.012","article-title":"Co-evolution of tumor cells and their microenvironment","volume":"25","author":"Polyak","year":"2009","journal-title":"Trends Genet"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00758","article-title":"Tumor microenvironment in ovarian cancer: function and therapeutic strategy","volume":"8","author":"Yang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101532","article-title":"Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1\u03b1 and tumor progression of clear cell ovarian cancer","volume":"5","author":"Mori","year":"2024","journal-title":"Cell Rep Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-1294","article-title":"Endometriosis-associated mesenchymal stem cells support ovarian clear cell carcinoma through iron regulation","volume":"82","author":"Atiya","year":"2022","journal-title":"Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.09.001","article-title":"Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management","volume":"151","author":"Oda","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.67","article-title":"Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium","volume":"30","author":"Willis","year":"2017","journal-title":"Mod Pathol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2018.10.11","article-title":"Characterization of PD-L1 expression and its prognostic value in patients with ovarian cancer","volume":"7","author":"Cheng","year":"2018","journal-title":"Transl Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0407","article-title":"The tumor microenvironment of clear-cell ovarian cancer","volume":"10","author":"Devlin","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225488","article-title":"Regulatory T cells in ovarian carcinogenesis and future therapeutic opportunities","volume":"14","author":"Cassar","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103568","article-title":"Signal integration by Akt regulates CD8 T cell effector and memory differentiation","volume":"188","author":"Kim","year":"2012","journal-title":"J Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002050","article-title":"MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis","volume":"186","author":"Hemon","year":"2011","journal-title":"J Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-10-59","article-title":"Induction of granzyme B expression in T-cell receptor\/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway","volume":"10","author":"Efimova","year":"2009","journal-title":"BMC Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13048-023-01179-1","article-title":"Lymphocyte-activation gene 3 protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis of ovarian clear cell carcinoma","volume":"16","author":"Zaitsu","year":"2023","journal-title":"J Ovarian Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3582","article-title":"ARID1A-mutated ovarian cancers depend on HDAC6 activity","volume":"19","author":"Bitler","year":"2017","journal-title":"Nat Cell Biol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e173290","DOI":"10.1001\/jamaoncol.2017.3290","article-title":"Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer","volume":"3","author":"Goode","year":"2017","journal-title":"JAMA Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2020.04.043","article-title":"Molecular subtypes of clear cell carcinoma of the endometrium: opportunities for prognostic and predictive stratification","volume":"158","author":"Kim","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1065773","article-title":"Combination of immune checkpoint blockade and targeted gene regulation of angiogenesis for facilitating antitumor immunotherapy","volume":"11","author":"Zhan","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA)","volume":"39","author":"Hamanishi","year":"2021","journal-title":"J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG Oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J Clin Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5500","article-title":"Final results of BrUOG 354: a randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas","volume":"42","author":"Dizon","year":"2024","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/ijgc-2021-003017","article-title":"Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9\/LEAP-001","volume":"32","author":"Marth","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.S2.P21","article-title":"Preliminary efficacy of pembrolizumab plus lenvatinib in recurrent clear cell gynecological cancer: phase II LARA trial (GCGS-OV4\/APGOT-OV3)","author":"Kim","year":"2024","journal-title":"Presented at: 39th Annu Meeting Korean Soc Gynecologic Oncol"},{"key":"B125","unstructured":"Pembrolizumab and lenvatinib in clear cell ovarian cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.04.011","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: results from the phase 2 multicohort LEAP-005 study","volume":"186","author":"Gonz\u00e1lez-Mart\u00edn","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101218","article-title":"Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy","volume":"48","author":"McNamara","year":"2023","journal-title":"Gynecol Oncol Rep"},{"key":"B128","unstructured":"A study of pembrolizumab in patients with advanced gynaecological clear cell cancer (PEACOCC)"},{"key":"B129","unstructured":"Sintilimab plus bevacizumab in recurrent\/persistent ovarian clear cell carcinoma (INOVA)"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/annonc\/annonc1054","article-title":"522MO Preliminary results of sintilimab (Sin)+bevacizumab (Bev) in recurrent\/persistent ovarian clear cell carcinoma (INOVA): a multicenter, single-arm, phase II trial","volume":"33","author":"Liu","year":"2022","journal-title":"Ann Oncol"},{"key":"B131","unstructured":"Study on pembrolizumab in recurrent, platinum resistant, CPS >1 positive ovarian, fallopian tube and primary peritoneal cancer patients (MITO 27)"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5565","article-title":"A multicenter phase II randomized trial of durvalumab (D) versus physician\u2019s choice chemotherapy (PCC) in patients with recurrent ovarian clear cell adenocarcinoma (MOCCA\/APGOT-OV2\/GCGS-OV3)","volume":"40","author":"Tan","year":"2022","journal-title":"J Clin Oncol"},{"key":"B133","unstructured":"A study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors (BOUQUET)"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1926","article-title":"747MO First results from the ENGOT-GYN2\/GOG-3051\/BOUQUET phase II biomarker-directed platform study: cobimetinib or atezolizumab + bevacizumab for persistent\/recurrent rare epithelial ovarian cancer","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"key":"B135","unstructured":"BrUOG 354 nivolumab +\/- ipilimumab for ovarian and extra-renal clear cell carcinomas"},{"key":"B136","unstructured":"Trial of lenvatinib plus pembrolizumab in recurrent gynecological clear cell adenocarcinomas (LARA)"},{"key":"B137","unstructured":"EON: A single-arm phase II study of etigilimab (OMP-313M32) in combination with checkpoint inhibition (Nivolumab) in patients with platinum-resistant, recurrent epithelial ovarian cancer"},{"key":"B138","unstructured":"A study of xmAb20717 (Vudalimab)in patients with selected advanced gynecologic and genitourinary Malignancies"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1302","article-title":"HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer","volume":"79","author":"Fukumoto","year":"2019","journal-title":"Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-0048-3","article-title":"Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors","volume":"32","author":"Jeong","year":"2014","journal-title":"Invest New Drugs"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25105","article-title":"Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children, adolescents and young adults with relapsed or refractory solid tumors","volume":"61","author":"Norris","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"B142","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canlet.2022.01.027","article-title":"HIF-1\u03b1 inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer","volume":"531","author":"Luo","year":"2022","journal-title":"Cancer Lett"},{"key":"B143","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13048-020-00751-3","article-title":"Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report","volume":"13","author":"Lin","year":"2020","journal-title":"J Ovarian Res"},{"key":"B144","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1038\/s41467-021-26407-4","article-title":"Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy","volume":"12","author":"Bent","year":"2021","journal-title":"Nat Commun"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-02297-2","article-title":"Expression of a soluble IL-10 receptor enhances the therapeutic effects of a papillomavirus-associated antitumor vaccine in a murine model","volume":"68","author":"Silva","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1238537","article-title":"Inhibitory mechanism of peptides with a repeating hydrophobic and hydrophilic residue pattern on interleukin-10","volume":"13","author":"Ni","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.18","article-title":"Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing","volume":"20","author":"Berezhnoy","year":"2012","journal-title":"Mol Ther"},{"key":"B148","volume-title":"Alpelisib","year":""},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.02.029","article-title":"Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity","volume":"183","author":"Passarelli","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1088962","article-title":"The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer","volume":"12","author":"Passarelli","year":"2023","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1661048\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:35:31Z","timestamp":1764138931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1661048\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":150,"alternative-id":["10.3389\/fimmu.2025.1661048"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1661048","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"article-number":"1661048"}}